BURKITT LYMPHOMA
Clinical trials for BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in about 215 adults with B-cell cancers like lymphoma that have come back or not responded to prior treatment. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to find the safest …
Matched conditions: BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 17, 2026 09:25 UTC
-
Experimental Dual-Targeting cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early study tests a new type of immune cell therapy (bispecific AbTCR-T cells) in 3 adults with B-cell lymphoma that has not responded to or returned after at least two prior treatments. The cells are designed to recognize and attack two cancer markers (CD19 and CD22) at onc…
Matched conditions: BURKITT LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC